← Patent-cliff monitor small molecule ZELSUVMI BERDAZIMER SODIUM
Loss of exclusivity July 2035 latest FDA-listed patent expiry
Company LNHC INC
Drug detail Brand name ZELSUVMI Active ingredient BERDAZIMER SODIUM Strength EQ 10.3% BASE Dosage form GEL Route TOPICAL Modality Small molecule FDA approval January 2024 Marketing status RX
Listed patents Patent Expires Type 10322081 July 2035 use U-3796 10736839 July 2035 use U-3792 11040006 July 2035 product 11723858 July 2035 product 10258564 November 2034 use U-3799 11285098 February 2034 product 9855211 February 2034 product 10265334 July 2032 product 9289442 July 2032 product 9526738 September 2031 product 10376538 August 2030 product 9737561 August 2030 use U-3802 8956658 May 2026 substance 8282967 May 2026 substance
Regulatory exclusivity Code Expires NCE January 2029
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.